

With respective opportunities associated and held by our affiliates, Oncology Will Be The Strategic Pillar For Future Growth, And Fosun Pharma Is Increasing Strategic Pipeline In Non-oncology Areas






PCC	IND	Phase 1	Phase 2	Phase 3	Filing	Approved
FKC211 (FOLR1 CAR-T) EOC	FCN-338 (BCL-2) AML/MDS	YP01001 (VEGFR,FGFR,RET) Solid Tumor	FH1701 (MEK1/2) NF1-Pediatric, LGG, LCH & ECD-Adult, LCH- Pediatric, AVM	FS-1502 (HER2 ADC) 2-4L BC	Avatrombopag (TPO) ITP	FKC876 (CD19 CAR-T) 2L&3L DLBCL
CWB005双抗 (EPO-R) GC/Pancreatic tumor	FCN159 (MEK) Pediatric LCH	FCN-338 (BCL-2) CLL/SLL, NHL(MCL)	FS-1502 (HER2 ADC) 2/3L GC/GEJ, Combo PD- 1 1L GC/GEJ	FH1701 (MEK1/2) NF1-Adult	Tenapanor (NHE-3) ESRD-HD	Avatrombopag (TPO) CLDT
XS-02 (CHK1) Solid tumor	SurVaxM (survivin) GBM	FH2001 (PD-L1/FGFR) Advanced Solid Tumor	SAF-189 (ALK/ROS1) ROS1+NSCLC	SAF-189 (ALK/ROS1) ALK+NSCLC	RT002 (DaxibotulinumtoxinA) Glabella Line	mRNA XBB. 1.5 COVID-19-Adult Macao
VS-S103 (GLP-1R/GCG- R /GIP-R) T2DM/Obesity/NASH	VT-101 Solid tumor	XH-S003 (Factor B) Immunology	FCN-338 (BCL-2) AML/MDS	FCN-437 (CDK4/6) Late-stage BC 1L, 2L	RT002 (DaxibotulinumtoxinA) Cervical Dystonia	Tenapanor(NHE-3) HK IBS-C
	XS-03 (PLK1) Solid tumor	SZEY-2108 (penicillin- binding protein) CRE	CWB001 Long-acting EPO CKD	FKC-876 (CD19 CAR-T) iNHL	mRNA XBB. 1.5 COVID-19-Adult HK	
	XS-04 (IRAK/BTK) Hematology	Tenapanor(NHE-3) IBS-C		FKC-889 (CD19 CAR-T) MCL, ALL		
	XH-S002 (FXIa) CV & Hematology	PA-824 MDR Tuberculosis		Opicapone (COMT) Parkinson's Disease		
	FH2201(QPCTL) Solid Tumor			ET-26 Anesthesia		
	XH-S004 (DPP1) Immunology			Fortacin Premature Ejaculation		
	OP0595 (β Lactam enzyme) Adult G- Bacterial Infection Grafalon (rabbit IgG) SCT					
	FCN-016 (ROCK) Glaucoma					

Note: 1. CLDT: thrombocytopenia caused by chronic liver

█ Oncology & Hematology
 █ Immunology
 █ Chronic disease
 █ Central Nervous System
 █ Others

With respective opportunities associated and held by our affiliates, Oncology and Immunology Will Be The Strategic Pillar For Henlius' Future Growth

IND	Phase I	Phase II	Phase III	NDA	Marketed
HLX51 OX40 Solid tumors, lymphoma	HLX10 ⁽¹⁾ (serplulimab)+HLX60 ⁽²⁾ PD-1+GARP Solid tumors	HLX10 ⁽¹⁾ (serplulimab)+HANBEITAI PD-1+VEGF mCRC 1L	HLX10 ⁽¹⁾ (serplulimab)+chemo PD-1 ES-SCLC 1L	HLX10 ⁽¹⁾ (serplulimab)+chemo PD-1 ES-SCLC 1L	HANSIZHUANG (serplulimab) ⁽¹⁾ PD-1 MSI-H solid tumors, sqNSCLC, ES-SCLC, ESCC
HLX6018 GARP/TGF-β1 IPF	HLX60 ⁽²⁾ GARP Solid tumors, lymphoma	HLX10 ⁽¹⁾ (serplulimab)+HLX07 PD-1+EGFR HNSCC, NPC, GC, ESCC, sqNSCLC	HLX10 ⁽¹⁾ (serplulimab) +chemo PD-1 Neo/adjuvant treatment for GC	HLX10 ⁽¹⁾ (serplulimab)+HANBEITAI PD-1+VEGF nsNSCLC 1L	HANLIKANG (rituximab) ⁽¹⁴⁾ CD20 NHL, CLL, RA ⁽¹⁵⁾
HLX17 (pembrolizumab) PD-1 MEL, NSCLC, EC, HNSCC, CRC, HCC, TNBC	HLX53 TIGIT Solid tumors, lymphoma	HLX10 ⁽¹⁾ (serplulimab)+HLX26+chemo PD-1+LAG-3 NSCLC 1L	HLX10 ⁽¹⁾ (serplulimab) +chemo +radio PD-1 LS-SCLC 1L	HLX02 (trastuzumab) ⁽¹²⁾ HER2 Breast cancer, mGC	HANQUYOU (trastuzumab) ⁽¹²⁾ HER2 Breast cancer, mGC
HLX99 Polypharmacology ALS	HLX42 ⁽⁴⁾ EGFR ADC Solid tumors	HLX07 ⁽⁶⁾ EGFR Solid tumors (cSCC)	HLX04-O ⁽⁸⁾ VEGF WetAMD	HANDAYUAN (adalimumab) ⁽¹³⁾ TNF-α PJIA, pediatric plaque psoriasis, etc.	HANDAYUAN (adalimumab) ⁽¹³⁾ TNF-α RA, AS, psoriasis, uveitis
	HLX43 ⁽³⁾ PD-L1 ADC Solid tumors	HLX22+HANQUYOU HER2+HER2 GC	HLX11 (pertuzumab) ⁽⁹⁾ HER2 Neoadjuvant treatment of breast cancer		HANBEITAI (bevacizumab) ⁽¹⁶⁾ VEGF mCRC, advanced, metastatic or recurrent NSCLC, GBM, etc.
	HLX05 (cetuximab) ⁽⁵⁾ EGFR mCRC, HNSCC	HLX208 ⁽⁷⁾ BRAF V600E LCH/ECD, solid tumors (i.e. MEL, TC, mCRC, NSCLC)	HLX14 (denosumab) ⁽¹⁰⁾ RANKL Osteoporosis		
	HLX15 (daratumumab) CD38 Multiple myeloma	HLX208 ⁽⁷⁾ +HLX10 ⁽¹⁾ (serplulimab) BRAF V600E+PD-1 NSCLC	HLX78 (Lasofoxifene) ⁽¹¹⁾ SERM Breast cancer		
	HLX13 (ipilimumab) CTLA-4 MEL, RCC, CRC, HCC, NSCLC, MPM, EC				

- Innovative mAb
- Innovative fusion protein
- mAb biosimilar
- Innovative ADC
- Innovative small molecule
-  Bridging study in the US
-  BLA under FDA review
-  MAA application in the EU
-  MRCT
-  The first Chinese mAb approved both in the Chinese mainland and the EU

(1) Approved in China and Indonesia, business partners: KGbio/Fosun Pharma/Intas. (2) IND approvals obtained in Australia. (3) IND approvals obtained in China/the US, and received fast track designation by FDA. (4) Business partner: Shanghai Jingze. (5) Business partner: Essex. (6) IND approvals obtained in China/the US. (7) Exclusive right in China. (8) IND approvals obtained in China/Australia/the US/Singapore/the EU countries, etc. Business partner: Essex. (9) IND approvals obtained in China/the EU. Business partner: Organon. (10) IND approvals obtained in China/the EU/Australia. Business partner: Organon. (11) Exclusive rights in China, MRCT phase III global enrolment is in process. (12) Approved in 40+ countries, including China, the UK, Germany, France and Australia, trade name registered in Europe: Zercepac®, trade name registered in Australia: Tuzucip® and Trastucip®. Business partners: Accord/ Cipla/ Jacobson/ Elea/ Eurofarma/ Abbott/KGbio. (13) Business partners: Wanbang/Getz Pharma. (14) The first biosimilar approved in China. Business partners: Fosun Pharma/FARMA DE COLOMBIA/ Eurofarma/Abbott. (15) The first rituximab approved for the indication in China. (16) Business partner: Eurofarma